



2010

PROGRAM

DECEMBER 8-12, 2010 □ 33RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
SAN ANTONIO TEXAS USA □ WWW.SABCS.ORG



SCHEDULE AT A GLANCE

Wednesday 12/8/10	Program Slots	Day 1 Thursday 12/9/10	Day 2 Friday 12/10/10	Day 3 Saturday 12/11/10	Day 4 Sunday 12/12/10
	7:00				
	7:30				
	8:00	Mentoring	Poster Session 2	Poster Session 4	Poster Session 6
	8:15		Poster Disc 3	Poster Disc 7	
	8:30	Welcome	Poster Disc 4	Poster Disc 8	
	8:45	Plen -			Year in Review Lectures
	9:00	<i>Metabolomics-Dang</i>	Plen -	Plen -	<i>Basics - Fuqua</i>
	9:15		<i>HER2 - Spector</i>	<i>Decisions - Ariely</i>	<i>Transl - Dowsett</i>
	9:30				<i>Early - Goldhirsch</i>
	9:45				<i>Late - Carey</i>
	10:00	General Session 1	General Session 3	General Session 5	
	10:15				
	10:30				
	10:45				
	11:00				
	11:15				
	11:30	Outstdg Invstgr	AACR Lecture	McGuire Lecture	
	11:45		<i>Ashworth</i>	<i>Sledge</i>	
	12:00	Lunch	Lunch	Lunch	
	12:15	12:00-1:35	12:00-1:35	12:00-1:35	
	12:30	Basic -	Basic -	Basic -	
	12:45	<i>Dormancy</i>	<i>Surv Paths</i>	<i>Stem Cells</i>	
	1:00	Clin -	Clin Case Disc	Clin Case Disc	
	1:15	<i>Screening</i>			
	1:30				
	1:45	Mini Symposium 1	Mini Symposium 2	Mini Symposium 3	
	2:00	<i>Non-coding RNAs</i>	<i>Surgical Topics</i>	<i>Disparities</i>	
	2:15				
	2:30				
	2:45				
	3:00				
	3:15	General Session 2			
	3:30		General Session 4	General Session 6	
	3:45				
	4:00				
	4:15				
	4:30	Komen Brinker Lectures			
	4:45				
	5:00				
	5:15				
	5:30				
	5:45	Poster Session 1	Poster Session 3	Poster Session 5	
	6:00				
	6:15	Poster Disc 1	Poster Disc 5	Poster Disc 9	
	6:30				
	6:45	Poster Disc 2	Poster Disc 6	Poster Disc 10	
	7:00				
	7:15				
	7:30				

Registration
12 Noon – 7 PM

Educational Sessions 1
2:00-3:30pm
CNS Mets
Gen. Testing
DNA Repair

Educational Sessions 2
4:00 - 5:30 pm
Biomarkers
Rad Techniques
Quant Imaging

Educational Sessions 3
6:00 - 7:30 pm
Next Gen Seq
Survival Sig
Symptom Mgt

For Exhibit Hours See Page ??

33RD ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM

PROGRAM SCHEDULE

(AT PRESS TIME)

Refer to www.sabcs.org for the most current information.

Room Locations

Exhibit Halls A, B, C & D: Street Level
Ballrooms A & B: Street Level
Ballroom C: Ballroom Level
Bridge Hall: Street Level

WEDNESDAY, DECEMBER 8, 2010

12:00-7:00 REGISTRATION – Bridge Hall

Pre-registered attendees can obtain materials. Those who have not yet registered may do so.

2:00-7:30 EDUCATIONAL SESSIONS – BALLROOM LEVEL – BALLROOM C

An update on advances in the technologies available for translational research. Sessions are to provide people with a better understanding of the talks they hear using the techniques described. They also provide researchers with a guide to the techniques they should be considering for their studies.

2:00-3:30 Educational Session

CNS Metastases in Breast Cancer: Current Challenges and Future Directions – Ballroom C-1

Moderator: Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA

Advances in neurosurgery in the management of CNS metastases

Elizabeth B. Claus, MD, PhD
Yale University
New Haven, CT

Radiation therapy for CNS metastases: What should the standard approach be?

Minesh P. Mehta, MD
University of Wisconsin School of Medicine and Public Health
Madison, WI

Systemic therapy for CNS metastases

Nancy U. Lin, MD
Dana-Farber Cancer Institute
Boston, MA

Translating new approaches from bench to bedside

Patricia S. Steeg, PhD
National Cancer Institute
Bethesda, MD

Panel Discussion

2:00-3:30 Educational Session

The Clinical Utility of Genetic Testing for Inherited Predisposition to Breast Cancer: BRCA and Beyond – Ballroom C-2

Moderator: Mark E. Robson, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

Evaluation of breast cancer predisposition in different clinical venues

Sharon E. Plon, MD, PhD
Baylor College of Medicine
Houston, TX

Management of women with a highly penetrant predisposition to breast cancer: State of the art 2010

Susan M. Domchek, MD
University of Pennsylvania
Philadelphia, PA

Challenges to clinical application of new discoveries in the genetics of breast cancer predisposition

Mark E. Robson, MD
Memorial Sloan-Kettering Cancer Center
New York, NY

2:00-3:30 Educational Session

DNA Repair – Ballroom C-3

Moderator: Daniel P. Silver, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

DNA repair pathways and tumorigenesis

James M. Ford, MD
Stanford University Medical Center
Stanford, CA

DNA repair and breast cancer: Therapeutic opportunities and challenges

Daniel P. Silver, MD, PhD
Dana-Farber Cancer Institute
Boston, MA

4:00-5:30 Educational Session

Design & Interpretation of Biomarker Studies – Ballroom C-1

Moderator: Mitchell Dowsett, MD, PhD
Royal Marsden Hospital NHS Trust
London, UNITED KINGDOM

Statistical challenges in predictive and prognostic biomarker studies: How to avoid wasting your time and specimens

Lisa M. McShane, PhD
National Cancer Institute
Bethesda, MD

The importance of technical validation

Jorge Reis-Filho, MD, PhD, MRCPATH
Breakthrough Breast Cancer Research Center
The Institute of Cancer Research
London, UNITED KINGDOM

Interpretation of biomarker studies

Lajos Pusztai, MD, DPhil
UT MD Anderson Cancer Center
Houston, TX

4:00-5:30 Educational Session

Emerging Radiation Techniques – The Fast and the Furious – Ballroom C-2

Moderator: Richard Crownover, MD, PhD
UT Health Science Center San Antonio
San Antonio, TX

Rationale and results of accelerated partial breast irradiation

Frank A. Vicini, MD, FACR
William Beaumont Hospital
Royal Oak, MI

Radical surgery and stereotactic body radiotherapy

Richard Crownover, MD, PhD
UT Health Science Center San Antonio
San Antonio, TX

4:00-5:30 Educational Session

Automated, Quantitative Cell and Tissue Imaging Technologies – Ballroom C-3

Moderator: Rachel Schiff, PhD
Baylor College of Medicine
Houston, TX

Measuring and modeling cell death pathways in tumor cells

Peter K. Sorger, PhD
Harvard Medical School
Boston, MA

Quantitative methods to assess eligibility for breast cancer therapy

David L. Rimm, MD, PhD
Yale University School of Medicine
New Haven, CT

6:00-7:30 **Educational Session**

Next Generation Sequencing for the Clinician – Ballroom C-1

Moderator: Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC

Next-generation sequencing and analysis of tumor/normal pairs

Elaine R. Mardis, PhD
Washington University
St. Louis, MO

Leveraging next generation sequencing in the study of breast cancer somatic genetics

Andrew Futreal, PhD
Wellcome Trust Sanger Institute
Cambridge, UNITED KINGDOM

6:00-7:30 **Educational Session**

Next Generation Sequencing for the Clinician – Ballroom C-1

Moderator: Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC

Next-generation sequencing and analysis of tumor/normal pairs

Elaine R. Mardis, PhD
Washington University
St. Louis, MO

Leveraging next generation sequencing in the study of breast cancer somatic genetics

Andrew Futreal, PhD
Wellcome Trust Sanger Institute
Cambridge, UNITED KINGDOM

Next generation sequencing for gene expression profiling

Charles M. Perou, PhD
University of North Carolina
Chapel Hill, NC

6:00-7:30 **Educational Session**

Systems Biology – Can it Explain Everything?

Moderator: Adrian V. Lee, PhD
UPMC
Pittsburgh, PA

Cancer systems biology: Concepts and perspectives?

Douglas A. Lauffenburger, PhD
Massachusetts Institute of Technology
Cambridge, MA

Modeling sensitivity to therapeutic agents

Paul T. Spellman, PhD
Lawrence Berkeley National Laboratory
Berkeley, CA

Systems biology for the clinician

Dana Faratian, MD, FRCPATH
Edinburgh Breakthrough Research Unit
University of Edinburgh
Edinburgh, UNITED KINGDOM

6:00-7:30 **Educational Session**

Symptom Management – Ballroom C-3

Moderator: Laura J. Esserman, MD, MBA
University of California San Francisco
San Francisco, CA

Balancing risks of deconditioning vs. weight-lifting for breast cancer survivors for Lymphedema

Kathryn H. Schmitz, PhD, MPH
University of Pennsylvania School of Medicine
Philadelphia, PA

Understanding the role of botanicals in the management of breast cancer

Debasish Tripathy, MD
University of Southern California
Los Angeles, CA

Long term management of pain due to, and after, primary treatment of breast cancer

Michael W. Rabow, MD
University of California San Francisco
San Francisco, CA

Losing your hair during chemotherapy may not be inevitable: emerging techniques to avoid hair loss

Hope S. Rugo, MD
University of California San Francisco
San Francisco, CA

THURSDAY, DECEMBER 9, 2010

7:00-8:30
for

Career Development Forum: A Networking Session for Young Investigators – Ballroom B

Networking and career development opportunities for early-career scientists. The session is open to early-career scientists, defined as graduate students, postdoctoral or clinical fellows, or medical students and residents, who are registered attendees of the SABCS. Space in the workshop is limited to 135 participants; registrations will be accepted on a first-come, first-served basis and is free of charge. Please complete the registration form on page ??, Discussion topics include Careers in Government; Careers in Industry, Careers in Translational Research, Grant Writing – Basic/Translational, Grant Writing – Clinical, How to Get the Most Out of Your Fellowship Years, How to Make the Most Out of Being A Cooperative Group Member, Making the Transition to Independence, Mentoring and Supervising, Negotiating a Job Offer or Promotion, Oral Presentation Skills, Publication Strategies, Searching for a Job and Interviewing, Setting Up and Managing a Laboratory, The Path Leading to Clinical Trials

8:30-8:45

WELCOME – Exhibit Hall D**Opening Remarks**

C. Kent Osborne, MD
Peter M. Ravdin, MD, PhD

8:45-9:15

PLENARY LECTURE 1 – Exhibit Hall D**Metabolic Reprogramming of Cancer Cells and Therapeutic Opportunities**

Chi Van Dang, MD, PhD
Johns Hopkins University School of Medicine
Baltimore, MD

9:15-11:30 GENERAL SESSION 1 – Exhibit Hall D

- 9:15 **11. Final analysis of NCIC CTG MA.27: A randomized phase III trial of Exemestane versus Anastrozole in postmenopausal women with hormone receptor positive primary breast cancer**
Goss PE, Ingle JN, Chapman J-AW, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Gelmon K, Shepherd L, Pritchard KI. Massachusetts General Hospital, Boston, MA, Mayo Clinic Rochester, MN, Queen's University, Kingston, ON, Canada, Washington University, St. Louis, MO, Indiana University Simon Cancer Center, Indianapolis, Cleveland Clinic, OH, University Institute of Medical Oncology Inselspital, Berne, Switzerland, British Columbia Cancer Agency, Vancouver, BC, Canada, Sunnybrook Health Sciences Centre, Toronto, ON.
- 9:30 **12. ACOSOG Z1031: A randomized neoadjuvant comparison between Letrozole (LET), Anastrozole (ANA) and Exemestane (EXE) for postmenopausal women with ER Rich stage 2/3 breast cancer: Biomarker outcomes and the predictive value of the baseline PAM50 based intrinsic subtype**
Ellis M, Suman V, Hoog J, Lin L, Snider J, Parker J, Deshryver K, Watson M, Allred C, Hunt K, Olson J. Washington University, St Louis, MO, Mayo Clinic, Rochester, MN, Duke University, Durham, NC, University of North Carolina, Chapel Hill, University of Texas, Houston.
- 9:45 **13. A comparison of Fulvestrant 500 mg with Anastrozole as first-line treatment for advanced breast cancer: Follow-up analysis from the 'FIRST' study**
Robertson JFR, Lindemann JPO, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Emerson L, Dean A, Ellis MJ. University of Nottingham, United Kingdom, AstraZeneca, United Kingdom, Hospital Arnau de Vilanova, Lleida, Spain, Centrum Instytut im M, Skłodowskiej-Curie, Krakow, Poland, FN Ostrava, Ostrava, Czech Republic, Ninewells Hospital and Medical School, Dundee, United Kingdom, Washington University School of Medicine, St Louis.
- 10:00 **14. A randomized, placebo-controlled, phase 2 study of AMG 479 with Exemestane (E) or Fulvestrant (F) in postmenopausal women with hormone-receptor positive (HR+) locally advanced (LA) or metastatic (M) breast cancer (BC)**
Kaufman PA, Ferrero JM, Bourgeois H, Kennecke H, De Boer R, Jacot W, McGreiv J, Suzuki S, Loh E, Robertson J. Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center, Lebanon, NH, Service Oncologie Medicale, Clinique Victor Hugo, British Columbia Cancer Agency, Department of Oncology and Haematology, CRLC Val d'Aurelle, Amgen Inc, Nottingham City Hospital.
- 10:15 **15. Interaction between Goserelin and Tamoxifen in a controlled clinical trial of adjuvant endocrine therapy in premenopausal breast cancer**
Sverrisdottir A, Johansson H, Johansson U, Bergh J, Rotstein S, Rutqvist LE, Fornander T. Karolinska Institutet and University Hospital, Stockholm, Sweden, Landspítali University Hospital, Reykjavik, Iceland, School of Cancer & Enabling Sciences, University of Manchester & Paterson Institute, Medical Oncology Breast Unit, Christie Hospital, Manchester, United Kingdom.
- 10:30 **16. TAMRAD: A GINECO randomized phase II trial of Everolimus in combination with Tamoxifen versus Tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to Aromatase inhibitors (AI)**
Bachelot T, Bourgier C, Cropet C, Guastalla J-P, Ferrero J-M, Leger-Falandry C, Soulie P, Eymard J-C, Debled M, Spaeth D, Legouffe E, Delozier T, El Kouri C, Chidiac J. Centre Leon Berard, Lyon, France, Institut Gustave Roussy, Villejuif, France, Centre Antoine Lacassagne, Nice, France, Centre Hospitalier Lyon-Sud, Pierre Benite, France, Centre Paul Papin, Angers, France, Institut Jean Godinot, Reims, France, Institut Bergonie, Bordeaux, France, Centre d'Oncologie de Gentilly, Nancy, France; Clinique de Valdegour, Nîmes, France; Centre François Baclesse, Caen, France; Centre Catherine de Sienne, Nantes, France; Hôpital Hôtel-Dieu, Paris, France.

- 10:45 **17. Lack of correlation between gene variants in Tamoxifen metabolizing enzymes with primary endpoints in the ATAC trial**
Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, Salter J, Pineda S, Cuzick J, Dowsett M. University of Michigan, Ann Arbor, University of Michigan, Royal Marsden Hospital, United Kingdom, Breakthrough Breast Cancer Research Centre, United Kingdom, Johns Hopkins University, CRUK Centre for Epidemiology, Mathematics and Statistics, United Kingdom.

- 11:00 **18. Outcome according to CYP2D6 genotype among postmenopausal women with endocrine-responsive early invasive breast cancer randomized in the BIG 1-98 trial**
Leyland-Jones B, Regan MM, Bouzyk M, Kammler R, Tang W, Pagani O, Maibach R, Dell'Orto P, Thurlimann B, Price KN, Viale G. BIG 1-98 Collaborative Group and International Breast Cancer Study Group, Bern, Switzerland.

- 11:15 **19. Discussion**
Matthew Goetz, MD, Mayo Clinic College of Medicine, Rochester, MN

- 11:30-12:00 ACR Outstanding Investigator Award for Breast Cancer Research, supported by an educational grant from**

Susan G. Komen for the Cure®

TBA

- 12:00-1:35 Lunch**

- 12:30-1:35 Clinical Science Forum – Ballroom A**

Controversies in Screening for Breast Cancer

Moderator: Eric P. Winer, MD
Dana-Farber Cancer Institute
Boston, MA

Rethinking and improving screening in the context of breast cancer biology

Laura J. Esserman, MD, MBA
University of California San Francisco
San Francisco, CA

Breast cancer screening – The radiology perspective

Christopher I. Flowers, MBBS
University of California San Francisco
San Francisco, CA

Panel Discussion

Laura J. Esserman, MD, MBA
University of California San Francisco
San Francisco, CA

Christopher I. Flowers, MBBS
University of California San Francisco
San Francisco, CA

Judy E. Garber, MD, MPH
Dana-Farber Cancer Institute
Boston, MA

Chris Tannous, PhD
Susan G. Komen for the Cure
Fountain Valley, CA

- 12:30-1:35 Basic Science Panel Discussions – Ballroom B**

Breast Cancer Recurrence and Tumor Dormancy – What is it? Does it matter?

Moderator: Lewis A. Chodosh, MD, PhD
University of Pennsylvania School of Medicine
Philadelphia, PA

Micrometastasis and dormancy in cancer patients

Klaus Pantel, MD, PhD
University Medical Center Hamburg-Eppendorf
Hamburg, GERMANY

- Models to mechanisms: Understanding tumor dormancy and breast cancer recurrence**
Lewis A. Chodosh, MD, PhD
University of Pennsylvania School of Medicine
Philadelphia, PA
- 1:45-2:45 MINI-SYMPOSIUM 1 – Exhibit Hall D**
- noncodingRNA - The New Frontier**
Moderator: Saraswati Sukumar, PhD
Johns Hopkins University School of Medicine
Baltimore, MD
- Long noncoding RNAs in breast cancer progression**
Howard Y. Chang, MD, PhD
Stanford University School of Medicine
Stanford, CA
- MicroRNA in medical practice**
George A. Calin, MD, PhD
UT MD Anderson Cancer Center
Houston, TX
- 2:45-4:30 GENERAL SESSION 2 – Exhibit Hall D**
- 2:45 21. Obesity at diagnosis is associated with inferior outcomes in hormone receptor positive breast cancer**
Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW, Wood WC, Fetting J, Davidson NE. Eastern Cooperative Oncology Group, Southwest Oncology Group, Cancer and Leukemia Group B, North Central Cancer Treatment Group.
- 3:00 22. Multivariate analysis of obesity and disease free survival in patients with nodal positive primary breast cancer - The ADEBAR trial**
Hepp PGM, Rack B, Annecke K, Wischnik A, Wolfgang S, Zwingers T, Harbeck N, Sommer HL, Friese K, Kiechle M, Janni W. Universitätsfrauenklinik Dusseldorf, Universitätsfrauenklinik Munchen, Frauenklinik Technische Universität München, Zentralklinikum Augsburg, Robert-Bosch-Krankenhaus Stuttgart, Estimate GmbH Augsburg, Brustzentrum der Universität Köln/Frechen, Klinikum Bad Trissl.
- 3:15 23. The impact of body mass index (BMI) on the efficacy of adjuvant endocrine therapy in postmenopausal hormone sensitive breast cancer (BC) patients; exploratory analysis from the TEAM study**
Seynaeve C, Hille E, Hasenburg A, Rea D, Markopoulos C, Hozumi Y, Putter H, Nortier H, van Nes J, Dirix L, van de Velde C. Erasmus MC Daniel den Hoed Cancer Center, Rotterdam, Netherlands, Leiden University Medical Center, Netherlands, University Hospital Freiburg, Germany, The University of Birmingham, United Kingdom, Athens University Medical School, Athens, Greece, Jichi Medical University, Shimotsuke, Japan, Sint Augustinus, Wilrijk, Belgium.
- 3:30 24. Final results of a prospectively planned biomarker analysis: HER1-3 as predictive markers of benefit from early treatment with aromatase inhibitors versus Tamoxifen in the TEAM pathology sub-study**
Bartlett JMS, Brookes CL, van de Velde CJH, Stocken D, Campbell FM, Hasenburg A, Kay C, Kiebeck D, Markopoulos C, Meershoek-Klein Kranenbarg E, Mallon EA, Dirix L, Robson T, Seynaeve C, Rea DW. University of Edinburgh, United Kingdom, University of Birmingham, United Kingdom, Leiden University Medical Centre, Netherlands, University Hospital, Freiburg, Germany, Helios Medical Centre, Aue, Germany, Athens University Medical School, Athens, Greece, Western Infirmary, Glasgow, United Kingdom, Az Augustinus, Antwerp, Belgium, Erasmus MC, Rotterdam, Netherlands.
- 3:45 25. Molecular profiling of aromatase inhibitor-treated post-menopausal breast tumours identifies determinants of response**
Dunbier AK, Ghazoui Z, Anderson H, Smith IE, Dowsett M. Institute of Cancer Research, London, United Kingdom, Royal Marsden Hospital, London, United Kingdom.
- 4:00 26. Aromatase inhibitors and risk of myocardial infarction, stroke and fracture**
Ligibel JA, O'Malley AJ, Fisher M, Daniel G, Winer EP, Keating NL. Dana-Farber Cancer Institute, Harvard Medical School, HealthCore, Inc.
- 4:15 27. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients**
Amir E, Ocana A, Niraula S, Carlsson L, Seruga B. Princess Margaret Hospital, Toronto, ON, Canada, Princess Margaret Hospital, Toronto, ON, Canada, Institute of Oncology Ljubljana, Slovenia.
- 4:30-5:30 SUSAN G. KOMEN FOR THE CURE BRINKER AWARDS FOR SCIENTIFIC DISTINCTION LECTURES – Exhibit Hall D**
- The Basic Science award is presented to a researcher who has added substantively to our understanding of the basic biology of, or development of, methodologies that further our ability to unravel the genetic and molecular basis of breast cancer. This year the award is being presented to:
- Jeffrey M. Rosen, Ph.D.**
Baylor College of Medicine
Houston, TX
Lecture Topic: Targeting of Breast Cancer Tumor Initiating Cells
- The Clinical Research award is presented to a clinician who has significantly furthered the identification of new prevention, detection or treatment approaches for breast cancer and its translation into clinical care. This year the award is being presented to an outstanding team:
- Soonmyung "Soon" Paik, MD**
NSABP Foundation Inc.
Pittsburgh, PA
Lecture Topic: "Prediction of benefit from systemic adjuvant therapies for breast cancer"
- 5:30-7:30 POSTER DISCUSSION 1 & RECEPTION – Ballroom A**
- Triple-Negative Breast Cancer – Signatures and Treatments** 101-108
- 5:30-7:30 POSTER DISCUSSION 2 & RECEPTION – Ballroom B**
- PD2 Stem Cells** 201-210
- 5:30-7:30 POSTER SESSION 1 & RECEPTION – Exhibit Halls A-B (#1001-11??)**
- Detection/Diagnosis**
- Axillary Staging and Sentinel Nodes 1001-1036
- Risk, Epidemiology and Prevention**
- Prevention - Behavioral Interventions 1037-1040
Prevention - Preclinical Studies and Model Systems 1041-1045
Prevention - Clinical Trials 1046-1049
Prevention - Nutritional Studies 1050-1053
- Social, Behavioral, Economic and Outreach Studies**
- Survivorship Research 1054-1066
Psychosocial Aspects 1067-1072
Cost Effectiveness 1073-1076
Practice and Society 1077-1080
- Treatment**
- Neoadjuvant Therapy 1081-1105
Bone Metastases 1106-1111
Managing Therapy-Related Toxicities 1112-1119
- Tumor Biology**
- DNA Damage and Repair 1120-1125
Cellular Mechanisms 1126-1131
Drug Resistance 1132-1143
Epigenetics 1144-1151
Stem/Progenitor Cells 1152-1163
Systems Biology of Breast Cancer 1164-1167

FRIDAY, DECEMBER 10, 2010

7:00-9:00 POSTER DISCUSSION 3 & CONTINENTAL BREAKFAST – Ballroom A

Metformin in Breast Cancer Prevention and Treatment 301-309

7:00-9:00 POSTER DISCUSSION 4 & CONTINENTAL BREAKFAST – Ballroom B

PD4 CTCs and DTCs 401-410

7:00-9:00 POSTER SESSION 2 & CONTINENTAL BREAKFAST – Exhibit Halls A-B (#2001-21??)

Prognosis and Response Predictions

Response Predictions - Biomarkers and Other Factors 2001-2045

Risk, Epidemiology and Prevention

Epidemiology - Population Studies 2046-2080

Treatment

Adjuvant Chemotherapy 2081-2093
Advanced Chemotherapy 2094-2099
Adjuvant Therapy – Other 2100-2104
Treatment: Advanced Therapy - Other 2105-2107
Male Breast Cancer 2108-2111
DCIS / LCIS 2112-2116

Tumor Biology

Biomarkers 2117-2147
Cell Cycle Regulation 2148-2153
Angiogenesis 2154-2159
Apoptosis and Senescence 2160-2161
Animal Models 2162-2166

9:00-9:30 PLENARY LECTURE 2 – Exhibit Hall D

Drug Development – Targeting HER2 Beyond Trastuzumab

Neil L. Spector, MD
Duke University Medical Center
Durham, NC

9:30-11:15 GENERAL SESSION 3 – Exhibit Hall D

9:30 **31. Lapatinib vs Trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy: Primary efficacy endpoint analysis of the GEPARQUINTO STUDY (GBG 44)**

Untch M, Loibl S, Bischoff J, Eidtmann H, Kaufmann M, Blohmer J-U, Hilfrich J, Strumberg D, Fasching PA, Kreienberg R, Tesch H, Hanusch C, Gerber B, Rezaei M, Jackisch C, Huober J, Kuehn T, Nekjudova V, von Minckwitz G. Helios Klinikum Berlin Buch, German Breast Group Neu-Isenburg, UFK Magdeburg, UFK Kiel, UFK Frankfurt / Main, St. Gertrauden Berlin, Henriettenstift Hannover, Marienhospital Herne, UFK Erlangen, UFK Ulm, Chop GmbH Frankfurt, Rot-Kreuz-Klinik Munchen, UFK Rostock, Luisenkrankenhaus Dusseldorf, Klinikum Offenbach, Kantonspital St. Gallen, Klinikum Esslingen.

9:45 **32. Neoadjuvant pertuzumab (P) and trastuzumab (H): Antitumor and safety analysis of a randomized phase II study ('NeoSphere')**

Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, Lluch-Hernandez A, Semiglazov V, Szado T, Ross G. Istituto Nazionale Tumori, Milan, Italy, Centrum Onkologii, Warsaw, Poland, Samsung Medical Center, Seoul, Korea, Leningrad Regional Oncology Dispensary, St Petersburg, Russian Federation, Taipei Veterans General Hospital, Taiwan, Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, Hospital Clinico Universitario, Valencia, Spain, NN Petrov Research Institute of Oncology, St Petersburg, Russian Federation, Roche Products Limited, Welwyn, United Kingdom

10:00

33. First results of the NeoALTTO trial (BIG 01-06/EGF 106903): A phase III, randomized, open label, neoadjuvant study of Lapatinib, Trastuzumab, and their combination plus Paclitaxel in women with HER2-positive primary breast cancer

Baselga J, Bradbury I, Eidtmann H, Di Cosimo S, Aura C, De Azambuja E, Gomez H, Dinh P, Fauria K, Van Dooren V, Paoletti P, Goldhirsch A, Chang T-W, Lang I, Untch M, Gelber RD, Piccart-Gebhart M, On behalf of the NeoALTTO Study Team. Vall d'Hebron University Hospital, Barcelona, Spain, FSS Ltd, Kincaig, United Kingdom, University Hospital Kiel, Germany, Breast Cancer Center Vall d'Hebron University Hospital and SOLTI (Spanish Breast Cancer Research Group), Barcelona, Spain, Institut Jules Bordet and Breast European Adjuvant Study Team, Brussels, Belgium, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru, Breast International Group, Brussels, Belgium, SOLTI (Spanish Breast Cancer Research Group), Barcelona, Spain, Breast European Adjuvant Study Team, Brussels, Belgium, GlaxoSmithKline, Collegeville, PA, European Institute of Oncology, Milan, Italy, National Cheng Kung University Hospital, Tainan, Taiwan, National Institute of Oncology, Budapest, Hungary, Academic Hospital of the University Charite, Berlin, Germany, Dana-Farber Cancer Institute, Boston, MA, Department of Medicine, Institut Jules Bordet, Brussels, Belgium.

10:15

34. Discussion

Eric P. Winer, MD, Dana-Farber Cancer Institute, Boston, MA

10:30

35. Discordance in hormone receptor and HER2 status in breast cancer during tumor progression

Lindstrom LS, Karlsson E, Wilking U, Bergh J. Karolinska Institute, Stockholm, Sweden; Karlstad Hospital, Karlstad, Sweden.

10:45

36. Combination therapy of the novel PI3K inhibitor GDC-0941 and dual PI3K/mTOR inhibitor GDC-0980 with Trastuzumab-DM1 antibody drug conjugate enhances anti-tumor activity in preclinical breast cancer models in vitro and in vivo

Sampath D, Fields C, Li G, Prior WW, Parsons K, Friedman LS, Lewis-Phillips GD. Genentech, South San Francisco, CA, Genentech, South San Francisco, CA.

11:00

37. Kinome screening for regulators of estrogen receptor identifies a novel kinase as a new therapeutic target in breast cancer

Giamas G, Filipovic A, Jacob J, Shifa BA, Green AR, Ellis IO, Lenz H-J, Stebbing J. Imperial College, London, United Kingdom, Queen's Medical Centre, Nottingham University Hospital, Nottingham, United Kingdom, University of Southern California, Norris Comprehensive Cancer Centre, Keck School of Medicine, Los Angeles, CA.

11:15

38. RNAi screening identifies the insulin/insulin-like growth factor-I receptor pathway as a mechanism of escape from hormone dependence in estrogen receptor-positive breast cancer

Fox EM, Miller TW, Ye F, Shyr Y, Arteaga CL. Vanderbilt-Ingram Comprehensive Cancer Center, Vanderbilt University, Nashville, TN.

11:30-12:00

AACR Distinguished Lectureship in Breast Cancer Research –Exhibit Hall D**Synthetic Lethal Approaches to Cancer Therapy**

Alan Ashworth, PhD, FMedSci, FRS
Breakthrough Research Centre at
The Institute of Cancer Research
London, UNITED KINGDOM

12:00-1:35

LUNCH BREAK

12:30-1:35

CASE DISCUSSION 1 – Ballroom A

12:30-1:35

BASIC SCIENCE FORUM – BALLROOM B**Managing Stress in Cancer Cells: New Druggable Pathways and Targets**

Moderator: C. Kent Osborne, MD
Baylor College of Medicine
Houston, TX

- Cancers are stressed too: exploiting cancer stress for new therapies** 3:45
Garth Powis, D.Phil.
UT MD Anderson Cancer Center
Houston, TX
- Molecular chaperones: Cancer dependence and druggability**
Paul Workman, PhD, DSc (Hon), FMedSci FSB
Cancer Research UK Centre of Cancer Therapeutics
The Institute Of Cancer Research
Sutton, UNITED KINGDOM
- 1:45-2:45 MINI-SYMPOSIUM 2 – Exhibit Hall D**
- Surgery**
Moderator: Ismail Jatoi, MD, PhD, FACS
UT Health Science Center San Antonio
San Antonio, TX
- Surgical considerations in early-stage breast cancer**
Lisa A. Newman, MD, MPH, FACS
University of Michigan Medical School
Ann Arbor, MI 4:00
- Recent U.S. trends in the local treatment of primary breast cancer**
Todd M. Tuttle, MD, MPH
University of Minnesota
Minneapolis, MN
- Nipple sparing mastectomy with intra operative radiotherapy**
Jean-Yves Petit
European Institute of Surgical Oncology
Milan, ITALY
- 3:15-5:30 GENERAL SESSION 4 – Exhibit Hall D**
- 3:15 **41. FinXX final 5-year analysis: Results of the randomised, open-label, phase III trial in medium-to-high risk early breast cancer**
Joensuu H, Kellokumpu-Lehtinen P-L, Huovinen R, Jukkola-Vuorinen A, Tanner M, Kokko R, Ahlgren J, Auvinen P, Bono P, Lindman H, On behalf of the FinXX Study Investigators. Helsinki University Central Hospital, Finland, Tampere University Hospital, Finland, Turku University Central Hospital, Finland, Oulu University Hospital, Oulu, Finland, Kanta-Hame Central Hospital, Hameenlinna, Finland, Gavle Hospital, Gavle, Sweden, Kuopio University Hospital, Kuopio, Finland, Uppsala University Hospital, Sweden. 4:30
- 3:30 **42. First efficacy results of a randomized, open-label, phase III study of adjuvant Doxorubicin plus Cyclophosphamide followed by Docetaxel with or without Capecitabine in high-risk early breast cancer**
O'Shaughnessy J, Devchand P, Stokoe C, Pippen Jr J, Blum JL, Krekow L, Holmes FA, Vukelja S, Lindquist D, Sedlacek S, Rivera R, Brooks R, McIntyre K, Pluenneke R, Schwartz J, Jones S, Brownstein C, Gilbert F. US Oncology, Dallas, TX, Rocky Mountain Cancer Center, Denver, CO, US Oncology, Plano, TX, US Oncology, Bedford, TX, US Oncology, Houston, TX, US Oncology, Tyler, TX, US Oncology, Sedona, AZ, US Oncology, El Paso, TX, US Oncology, Tucson, AZ, US Oncology, Dallas, TX, Kansas City Cancer Center North, MO, F Hoffmann-La Roche Inc, Nutley, NJ, F Hoffmann-La Roche Ltd, Basel, Switzerland. 4:45
- 43. Ten-year follow-up analysis of the BICRG 001 trial confirms superior DFS and OS benefit of adjuvant TAC (Docetaxel, Doxorubicin, Cyclophosphamide) over FAC (fluorouracil, Doxorubicin, Cyclophosphamide) in women with operable node-positive breast cancer**
Martin M, Mackey J, Pienkowski T, Rolski J, Guastalla J-P, Sami A, Gaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano M, Vinholes J, Pinter T, Childs B, Roessner M, Wilson V, Rupin M, Vogel C, on behalf of the BICRG 001 Investigators. Cross Cancer Institute, Edmonton, Canada, GEICAM, Madrid, Spain, Cancer Centre, Warsaw, Poland, Cancer Center, Krakow, Poland, Centre Leon Berard, Lyon, France, Saskatoon Cancer Centre, SK, Canada, TORI, Los Angeles, National Institute of Oncology, Budapest, Hungary, Christie Hospital, Manchester, United Kingdom, Stockholm Soder Hospital, Sweden, The Sarah Cannon Cancer Center, Nashville, TN, Weston Park Hospital, Sheffield, United Kingdom, Arizona Clinical Research Center, Tucson, Clinica de Oncologia de Porto Alegre, Porto Alegre, Brazil, Petz Aladar County Hospital, Gyor, Hungary, Sanofi-Aventis, Bridgewater, CIRG, Edmonton, Canada, Lynn Cancer Institute, Boca Raton. 5:00
- 44. SECRAB: The optimal sequencing of adjuvant chemotherapy (CT) and radiotherapy (RT) in early breast cancer (EBC), results of a UK multicentre prospective randomised trial**
Fernando IN, Bowden SJ, Buckley L, Grieve R, Spooner D, Agrawal RK, Brunt AM, Stockdale AD, Churn MJ, Stevens A, Marshall A, Canney P. University Hospitals Birmingham NHS Foundation Trust, United Kingdom, University of Birmingham, United Kingdom, University Hospital, Coventry, United Kingdom, Shrewsbury and Telford Hospital NHS Trust, Shrewsbury, United Kingdom, University Hospitals North Staffordshire, Stoke-on-Trent, United Kingdom, New Cross Hospital, Wolverhampton, United Kingdom, University of Warwick, United Kingdom, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. 5:00
- 45. Adjuvant treatment with Zoledronic Acid in stage II/III breast cancer. The AZURE Trial (BIG 01/04)**
Coleman RE, Thorpe HC, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Davies C, Bell R. Weston Park Hospital, Sheffield, United Kingdom, University of Leeds, United Kingdom, AZURE (BIG 01/01) Investigators. 5:15
- 46. Neoadjuvant chemotherapy with or without Bevacizumab: Primary efficacy endpoint analysis of the GEPARQUINTO Study (GBG 44)**
von Minckwitz G, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Kreienberg R, Solbach C, Gerber B, Jackisch C, Kunz G, Blohmer J-U, Huober J, Hauschild M, Fehm T, Loibl S, Nekljudova V, Untch M. German Breast Group, Neu-Isenburg, UFK Kiel, Luisenkrankenhaus Dusseldorf, UFK Erlangen, Chop GmbH, Frankfurt, UFK Magdeburg, Henriettenstift Hannover, Praxisklinik Berlin, Rot-Kreuz-Klinikum Munchen, UFK Ulm, UFK Frankfurt, UFK Rostock, Klinikum Offenbach, St. Johannes Hospital Dortmund, St. Gertrauden Berlin, Kantonspital St. Gallen, Frauenklinik Rheinfelden, UFK Tubingen, Klinikum Berlin-Buch. 5:15
- 47. Promoter CpG Methylation of BRCA1 predicts sensitivity to PARP inhibitors in breast cancer**
Veeck J, Ropero S, Setien F, Gonzalez-Suarez E, Osorio A, Benitez J, Herman JG, Tjan-Heijnen VC, Esteller M. Bellvitge Institute for Biomedical Research, Barcelona, Spain, Maastricht University Medical Centre, Netherlands, Spanish National Cancer Research Centre, Madrid, Spain, Johns Hopkins University School of Medicine, Baltimore, MD. 5:15
- 48. Comparing the prediction of chemotherapy benefit in patients with node-negative, ER-positive breast cancer using the recurrence score and a new measure that integrates clinical and pathologic factors with the recurrence score**
Tang G, Costantino JP, Crager M, Shak S, Wolmark N. NSABP, Pittsburgh, PA, Genomic Health Inc., Redwood City, CA. 5:15
- 49. TBA**

5:30-7:30 POSTER DISCUSSION 5 & RECEPTION – Ballroom A

Endocrine Resistance	501-511
-----------------------------	---------

5:30-7:30 POSTER DISCUSSION 6 & RECEPTION – Ballroom B

Local and Axillary Treatment	601-610
-------------------------------------	---------

5:30-7:30 POSTER SESSION 3 & RECEPTION – Exhibit Halls A-B (#3001-31??)**Detection/Diagnosis**

Circulating Tumor Cells	3001-3016
Micrometastases	3017-3021
Circulating Markers	3022-3028

Prognosis and Response Predictions

Prognostic Factors and Biomarkers – Preclinical	3029-3044
Biomarkers – Methods	3045-3053
Prognosis and Response Predictions – Other	3054-3056

Risk, Epidemiology, and Prevention

Epidemiology - Genetic and Molecular	3057-3064
Ethnic/Racial Aspects	3065-3073

Social, Behavioral, Economic, and Outreach Studies

Research Resources	3074-3076
Disparities and Barriers to Care	3077-3084
Advocacy	3085

Treatment

Adjuvant Therapy – Targeted	3086-3088
Advanced Therapy – Targeted	3089-3097
Alternative Therapies	3098-3101
Surgery	3102-3120

Tumor Biology

Novel/Emerging Therapeutic Targets	3121-3145
Novel Models	3146
Oncogenes / Tumor Suppressor Genes	3147-3161
Tumor Heterogeneity / Molecular Subclassification	3162-3168

SATURDAY, DECEMBER 11, 2010**7:00-9:00 POSTER DISCUSSION 7 & CONTINENTAL BREAKFAST – Ballroom A**

Markers in Neoadjuvant Therapy	701-710
---------------------------------------	---------

7:00-9:00 POSTER DISCUSSION 8 & CONTINENTAL BREAKFAST – Ballroom B

Survivorship Research	801-810
------------------------------	---------

7:00-9:00 POSTER SESSION 4 & CONTINENTAL BREAKFAST– Exhibit Halls A-B (#4001-4173)**Detection/Diagnosis**

Screening and Detection	4001-4013
Breast Imaging – Mammography	4014-4015
Breast Imaging – MRI	4016-4027
Radiology	4028

Prognosis and Response Predictions

Prognostic Factors and Biomarkers - Clinical Testing and Validation I	4029-4068
---	-----------

Risk, Epidemiology, and Prevention

Familial Breast Cancer - Genetic Testing	4069-4079
--	-----------

Treatment

Adjuvant Endocrine Therapy	4080-4093
Advanced Endocrine Therapy	4094-4099
Radiation Therapy	4100-4115
Breast Conservation	4116-4127

Tumor Biology

Immunology and Immunotherapy	4128-4135
Hormonal Factors and Receptors	4136-4158
Tumor Microenvironment	4159-4166
Growth Factors	4167-4172
Tumor Biology – Other	4173

9:00-9:30 PLENARY LECTURE 3 – Exhibit Hall D**The Upside of Irrationality**

Dan Ariely, PhD
Duke University
Durham, NC

9:30-11:15 GENERAL SESSION 5– Exhibit Hall D

9:30

51. Prospective long term outcomes for patients with micro- and macro-positive sentinel nodes: NSABP B-32 sentinel node trial

Julian TB, Anderson SJ, Golesorkhi N, Fourchotte V, Mamounas EP, Wolmark N. NSABP Operations and Biostatistical Centers, Pittsburgh, PA, Allegheny General Hospital, Pittsburgh, PA, Virginia Hospital Center, Arlington, VA, Institute Curie, Paris, France, Aultman Health Foundation, Canton, OH.

9:45

52. Letrogenic displacement of tumor cells to the sentinel node after surgical excision biopsy in primary breast cancer

Tvedskov TF, Jensen M-B, Kroman N, Balslev E. Copenhagen University Hospital, Copenhagen, Denmark, Danish Breast Cancer cooperative Group, Copenhagen, Denmark, Herlev Hospital, Herlev, Denmark.

10:00

53. Is manual lymph drainage applied after axillary lymph node dissection for breast cancer effective to prevent arm lymphoedema? A randomised controlled trial

Devoogdt N, Christiaens M-R, Geraerts I, Truijen S, Smeets A, Leunen K, Neven P, Van Kampen M. University Hospitals Leuven, Belgium, University Hospitals Leuven, Belgium, Artesis University College, Antwerp, Belgium.

10:15

54. Synthetic-lethality of triple-negative breast cancers via the MYC oncogene pathway

Goga A, Horiuchi D, Kusdra L, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, Huskey NE, Creasman KJ, Davis SE, Mills GB, Esserman LJ. University of California, San Francisco, Boston University School of Medicine, M.D. Anderson Cancer Center.

10:30

55. Identification of a clinically relevant gene signature in triple negative and basal like breast cancer

Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaberle E, Hankaer L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Muller V, Holtrich U, Kaufmann M. Goethe-University, Frankfurt, Germany, University of Muenster, Germany, University of Texas M.D. Anderson Cancer Center, Houston, Ludwig-Maximilians University, Munich, Germany, J. Gutenberg-University, Mainz, Germany, University of Hamburg, Germany.

10:45

56. Steroid hormone regulation of mammary stem cell function

Lindeman GJ, Asselin-Labat M-L, Vaillant F, Sheridan JM, Pal B, Wu D, Simpson ER, Yasuda H, Smyth GK, Martin JT, Visvader JE. The Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia, The Royal Melbourne Hospital, Melbourne, VIC, Australia, Prince Henry's Institute of Medical Research, Clayton, VIC, Australia, Nagahama Institute for Biochemical Science, Nagahama, Shiga, Japan, St Vincent's Institute, Fitzroy, VIC, Australia.

- 11:00 **57. Estrogen receptor alpha negative (ER-) breast cancer stem cells in ER+ cell lines and primary cancers are enriched by Tamoxifen therapy** 3:15
 O'Brien CS, Howell SJ, Gandhi A, Gee J, Lykkesfeldt A, Nicholson RI, Clarke RB. University of Manchester, United Kingdom, Christie Hospital NHS Foundation Trust, Manchester, United Kingdom, University Hospital of South Manchester, Manchester, United Kingdom, University of Cardiff, Wales, United Kingdom, Danish Cancer Society, Copenhagen, Denmark.
- 11:15-12:00 William L. McGuire Memorial Lecture – Exhibit Hall D**
Supported by GlaxoSmithKline.
- What Would Bill Do? Channeling Your Inner McGuire** 3:30
 George W. Sledge, Jr., MD
 Indiana University Simon Cancer Center
 Indianapolis, IN
- 12:00-1:35 LUNCH**
- 12:30-1:35 CASE DISCUSSION 2 – Ballroom A**
- 12:30-1:35 BASIC SCIENCE FORUM – Ballroom B**
- Stem Cells - Defying Definition?**
 Moderator: Jorge Reis-Filho, MD, PhD, MRCPATH
 Breakthrough Breast Cancer Research Center
 The Institute of Cancer Research
 London, UNITED KINGDOM 4:00
- Stem cells and cancer, 2 faces of self renewal**
 Michael F. Clarke, MD
 Stanford University School of Medicine
 Stanford, CA
- Understanding stem cells to get abreast of breast cancer**
 Geoffrey Lindeman, PhD, FRACP
 The Walter and Eliza Hall Institute of Medical Research
 Parkville, AUSTRALIA 4:15
- 1:45-3:00 MINI-SYMPOSIUM 3 – Exhibit Hall D**
- Breast Cancer Health Disparities**
 Moderator: Amelie G. Ramirez, Dr. PH, MPH
 UT Health Science Center San Antonio
 San Antonio, TX
- Advance in breast cancer risk assessment screening and prevention: Adapting the lessons to an underserved Latin population** 4:30
 Jeffrey N. Weitzel, MD
 City of Hope National Medical Center
 Duarte, CA
- The role of providers in breast cancer disparities** 4:45
 Nancy L. Keating, MD, MPH
 Harvard Medical School
 Boston, MA
- African ancestry and high-risk breast cancer**
 Lisa A. Newman, MD, MPH, FACS
 University of Michigan Medical School
 Ann Arbor, MI
- 3:00-5:30 GENERAL SESSION 6 – Exhibit Hall D**
- 3:00 **61. Menopausal hormone therapy influence on cancer incidence and related cancer mortality in the Women's Health Initiative Randomized Trials** 5:00
 Chlebowski RT. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA.
- 62. 313 patients with breast cancer during pregnancy - results from a prospective and retrospective registry (GBG-20/BIG02-03)**
 Loibl S, Amant F, Kaufmann M, Ring A, Silyeny H, Giermek J, Fehm T, Bontenbal M, Heinrigs M, Lenhard M, Scherr I, Mehta K, von Minckwitz G. German Breast Group, Neu-Isenburg, Germany, UZ Leuven Campus Gasthuisberg, Belgium, Universitäts-Frauenklinik Frankfurt a.M., Germany, Royal Sussex County Hospital, Brighton, United Kingdom, Cancer Center and Institute of Oncology, Warszawa, Poland, Universitäts-Frauenklinik Tubingen, Germany, Erasmus Medical Center, Rotterdam, Netherlands, Klinikum der Universität München, Germany, Klinikum der Universität München, Germany, Elisabeth Krankenhaus Kassel, Kassel, Germany.
- 63. Compliance with Mammographic Screening Guidelines from an Administrative Claims Database**
 Subar M, Lust SA, Lin W. Medco Research Institute, Franklin Lakes, NJ.
- 64. Association between prescription co-payment amount and compliance with adjuvant aromatase inhibitor therapy in women with early stage breast cancer**
 Neugut AI, Subar M, Wilde ET, Stratton S, Brouse CH, Hillyer G, Grann V, Hershman DL. Columbia University Medical Center, New York, NY, Mailman School of Public Health, New York, NY, Mailman School of Public Health, New York, NY, Medco Health Solutions, Inc., Franklin Lakes, NJ.
- 65. Prognostic relevance of circulating tumor cells in the peripheral blood of primary breast cancer patients**
 Rack B, Schindlbeck C, Adergassen U, Lorenz R, Zwingers T, Schneeweiss A, Lichtenegger W, Beckmann MW, Sommer H, Pantel K, Friese K, Janni W. Ludwig-Maximilians University, Munich, Womenas Hospital Traunstein-Trostberg, Gynecological Practice Dr. Lorenz/ Dr. Hecker, Braunschweig, Estimate GmbH, University of Heidelberg, Charite University Hospital Berlin, University of Erlangen, Institute for Tumorbiology, University Hamburg-Eppendorf, Heinrich-Heine University.
- 66. High independent prognostic and predictive value of circulating tumor cells in a large prospective multicenter trial including serum tumor markers in first line chemotherapy metastatic breast patients**
 Pierga J-Y, Bachelot T, Delalogue S, Brain E, Campone M, Asselain B, Mathiot C, Hajage D, Bidard F-C. Institut Curie, Paris, France, Centre Leon Berard, Lyon, France, Institut Gustave Roussy, Villejuif, France, Institut Curie, Saint Cloud, Centre Rene Gauducheau, Nantes, France.
- 67. Establishment and Characterization of Human Luminal Breast Cancer Xenografts**
 Cottu PH, Assavag F, De Plater L, Elbaz C, Karboul N, Marangoni E, Guvader C, Boudou-Rouquette P, Fontaine J-J, Gentien D, Vincent-Salomon A, Reyat F, de Cremoux P, Decaudin D. Institut Curie, Paris, France; Ecole Nationale Vétérinaire d'Alfort, Maisons Alfort, France..
- 68. Hedgehog ligand overexpression predicts poor outcome in breast cancer and is a potential therapeutic target for metastatic disease**
 O'Toole SA, Machalek D, Shearer R, Millar EKA, Nair R, Martelotto L, McLeod D, Cooper C, Ru Qiu M, Sutherland RL, Watkins DN, Swarbrick A. Garvan Institute of Medical Research, Darlinghurst, NSW, Australia, Royal Prince Alfred Hospital, Camperdown, NSW, Australia, University of NSW, Randwick, Australia, Sydney Medical School, Camperdown, NSW, Australia, St George Hospital, Kogarah, NSW, Australia, Monash Institute of Medical Research, Clayton, VIC, Australia, ICPMR Westmead Hospital, Westmead, NSW, Australia.
- 69. Expression of hedgehog proteins in the epithelial and stromal compartments of primary breast tumors and its prognostic significance**
 Ramaswamy B, Li X, Nuovo G, Lu Y, Shapiro CL, Majumder S. The Ohio State University, Columbus, OH.
- 5:15 **TBA**

5:30-7:30 POSTER DISCUSSION 9 & RECEPTION – Ballroom A**Obesity and Breast Cancer** 901-908**5:30-7:30 POSTER DISCUSSION 10 & RECEPTION – Ballroom B****HER-2 and ER Testing** 951-960**5:30-7:30 POSTER SESSION 5 & RECEPTION - Exhibit Halls A-B (#5001-5169)****Detection/Diagnosis**

Molecular, Functional, and Novel Imaging	5001-5016
Breast Imaging - Other Methods	5017-5030
Detection / Diagnosis – Other	5031-5034

Social, Behavioral, Economic and Outreach Studies

Quality of Life - Supportive Care	5035-5051
Palliation and Support (Pain Management)	5052

Treatment

Novel Targets and Targeted Agents	5053-5076
Signal Transduction Inhibitors	5077-5080
Her2-Targeted Therapy	5081-5114
Treatment – Other	5115-5123

Tumor Biology

Endocrine Therapy and Resistance	5124-5149
Metabolism and Breast Cancer	5150-5155
Etiology / Carcinogenesis	5156-5158
Gene Therapy	5159
Genetics - Germline Changes	5160-5163
Genetics - Somatic Changes	5164-5169

8:30-10:30 YEAR IN REVIEW

Moderator: C. Kent Osborne, MD,
Baylor College of Medicine,
Houston, TX

Advances in basic breast cancer research

Suzanne A.W. Fuqua, PhD
Baylor College of Medicine
Houston, TX

Translational breast cancer research

Mitchell Dowsett, MD, PhD
Royal Marsden Hospital NHS Trust
London, UNITED KINGDOM

Early breast cancer

Aron Goldhirsch, MD
European Institute of Oncology
Milan, ITALY

Progress in advanced breast cancer

Lisa A. Carey, MD
University of North Carolina
Chapel Hill, NC

10:30**ADJOURNMENT****SUNDAY, DECEMBER 12, 2010****7:00-8:30 POSTER SESSION 6 & CONTINENTAL BREAKFAST – Exhibit Hall C (#6001-6174)****Detection/Diagnosis**

Diagnostic Pathology	6001-6020
Biopsy Techniques	6021-6022

Prognosis and Response Predictions

Prognostic Factors and Biomarkers - Clinical Testing and Validation II	6023-6061
---	-----------

Risk Factors, Epidemiology, and Prevention

Risk Factors and Modeling	6062-6073
---------------------------	-----------

Social, Behavioral, Education, and Outreach Studies

Education	6074-6078
Doctor-Patient Communication	6079-6082

Treatment

Anti-angiogenic Therapy	6083-6093
Antibody-Based Regimens	6094-6096
New Drugs and Treatment Strategies	6097-6117

Tumor Biology

Molecular Profiles	6118-6133
Genomics	6134-6139
Tumor Progression, Invasion, and Metastasis	6140-6174